Drug Type Small molecule drug |
Synonyms ONO 2952 |
Target |
Mechanism TSPO inhibitors(Translocator protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC22H20ClFN2O2 |
InChIKeyZBQMTQGDBFZUBG-NRFANRHFSA-N |
CAS Registry895169-20-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pain | Phase 2 | US | 01 Jun 2013 | |
Irritable Bowel Syndrome | Phase 2 | US | 01 Apr 2013 | |
Multiple Sclerosis | Preclinical | JP | - |
Not Applicable | - | - | ONO-2952 60mg | zeblhggegd(xvxvupurhz) = The majority of AEs were mild in intensity and unrelated to study drug. A similar pattern of central nervous system (CNS) AEs was observed across all treatment groups and there were no clinically significant AEs related to the CNS. spjktgxmyr (vggmwcgevx ) View more | - | 01 Oct 2015 | |
Placebo |